15.097 articles found

Uncovering α-synuclein and tau burden in Alzheimer's and Lewy body diseases.

Quintin S, Paterno G, Lloyd GM, Prokop S, Giasson BI.

Brain Commun · 2025-09-02

DOI: 10.1093/braincomms/fcaf324PMID: 41069426

Challenges and Opportunities of Early Parkinson's Disease Biomarkers: α-Synuclein, Leucine-Rich Repeat Kinase 2 (LRRK2), DJ-1, and microRNAs.

Heineman A, Linck J, Eylon A, Parmar MS.

Cureus · 2025-09-02

DOI: 10.7759/cureus.91510PMID: 41050048

Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2.

Park JH, Chung KC.

J Biol Chem · 2025-09-02

DOI: 10.1016/j.jbc.2025.110675PMID: 40907896

Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy

Flores‐León M, Outeiro TF.

The FEBS Journal · 2025-09-01

Absence of Rab39b-induced macroautophagy impairment increases neurotoxic α-synuclein and causes degeneration of substantia nigra dopaminergic neurons in mouse model of X-linked Parkinson's disease

Chiu CC, Weng YH, Yeh TH, Chen WS, Liu S, Chiu TJ, Li AHL, Wang H.

Life sciences · 2025-09-01

Genetic basis of maneb-induced dopaminergic neurodegeneration in Drosophila.

Villalobos-Cantor S, Arreola-Bustos A, Martin I.

G3 (Bethesda) · 2025-09-01

DOI: 10.1093/g3journal/jkaf159PMID: 40644377

Restoration of Lysosomal Hydrolase Activities by LRRK2 Inhibition in GBA1- and LRRK2-Associated Parkinson's Disease Patient-Derived Cells.

Usenko TS, Basharova KS, Bezrukova AI, Grigor'eva EV, Pavlova SV, Baydakova GV, Nikolaev MA, Gaponenko IN, Khegay OV, Miliukhina IV, Zakharova EY, Pchelina SN.

J Neurochem · 2025-09-01

DOI: 10.1111/jnc.70214PMID: 40899651

Genetic association and potential mediators between subjective well-being and cardiovascular events: A bidirectional two-sample, two-step Mendelian randomization study.

Shen R, Lyu Y, Yang C, Zou S, Xu Y.

Medicine (Baltimore) · 2025-09-01

DOI: 10.1097/md.0000000000044482PMID: 40958224

Subthalamic Nucleus Deep Brain Stimulation in Early-onset Parkinson's Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers.

Otmani HE, Daghi M, Abdallaoui M, Moutawakil BE, Rafai MA, Jouti NT, Lesage S, Lakhdar A.

Basic Clin Neurosci · 2025-09-01

DOI: 10.32598/bcn.2025.7579.1PMID: 42220929

Phosphatidylinositol 3-phosphate metabolism impacts cellular α-synuclein localization in Saccharomyces cerevisiae.

Löser T, Bekbulat F, Behl C, Schepers J.

J Biol Chem · 2025-09-01

DOI: 10.1016/j.jbc.2025.110666PMID: 40902974

Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies.

Churchill L, Ignatavicius A, Konuri A, Anderson J, Taylor N, Lewis SJG, Matar E.

Mov Disord · 2025-09-01

DOI: 10.1002/mds.70025PMID: 40891082

Selective Stabilization of LRRK2 Kinase Conformations Reveals Distinct Modes of Action for Type I and II Inhibitors.

Wei C, Heh CH, Chin SP.

Cell Biochem Biophys · 2025-09-01

DOI: 10.1007/s12013-025-01877-1PMID: 40888827